HPA-12
Based on 1 publication(s) in Google Scholar
HPA-12 is a blood-brain barrier-permeable small-molecule inhibitor of ceramide transfer protein (CERT) with four stereoisomers (the (1R,3R)-stereoisomer exhibits the highest activity). HPA-12 blocks the transport of ceramide from the endoplasmic reticulum to the Golgi apparatus by binding to the START domain of CERT, leading to intracellular ceramide accumulation and inhibition of sphingomyelin (SM) synthesis. HPA-12 induces endoplasmic reticulum stress via the GRP78/ATF6/CHOP axis and activates mitochondrial autophagy, thereby inhibiting cell growth and inducing apoptosis. In in vivo experiments, HPA-12 significantly reduces the leukemia burden and splenomegaly in mouse models of acute myeloid leukemia (AML) and prolongs survival. HPA-12 is applicable for the research of lipid metabolism in acute myeloid leukemia and Alzheimer's disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.4%
- CAS. Nr.: 383418-30-2
- Formel: C22H37NO3
- Molecular Weight:363.53
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) HPA-12
More
Biologische Aktivität
Beschreibung
In Vitro
HPA-12 (60-100 μM; 48 h) reduces the viability and proliferation of FLT3ITD+ MV4-11 and Molm13 acute myeloid leukemia (AML) cell lines in a dose-dependent manner, but exerts no effect on FLT3-WT AML cell lines after 48 h of treatment[1].
Treatment with HPA-12 (100 μM; 48 h) induces apoptosis in FLT3ITD+-type Molm13 AML cells[1].
HPA-12 (2.5 μM; 30 min) inhibits CERT-mediated intracellular trafficking of fluorescent ceramide analogs in HeLa cells and prevents the accumulation of such analogs in the perinuclear Golgi region[2].
HPA-12 (0.1-2.5 μM; 2-5 h) potently and concentration-dependently inhibits de novo SM synthesis in CHO cells, exerts weak effects on Cer and GlcCer synthesis, and has no impact on the synthesis of phosphatidylethanolamine or phosphatidylserine[3].
HPA-12 (2.5 μM; 48 h) reduces the content of SM by approximately 30% in CHO cells, while increasing the content of glycosphingolipids, without altering the content of total phospholipids or Cer, nor inhibiting the synthesis of PC (1 μM HPA-12; 4 h)[3].
HPA-12 (20 μM; 10 min-1 h) is not an in vitro inhibitor of SM synthase or other key enzymes involved in de novo sphingolipid synthesis[3].
(1R,3R)-HPA-12 (1 μM; 15 min pre-treatment + 30 min exposure) primarily inhibits the ATP-dependent pathway of ceramide transport from the endoplasmic reticulum to sphingomyelin (SM) synthesis sites in CHO cells[3].
(1R,3R)-HPA-12 (2.5 μM; 0-120 min) does not inhibit the trafficking of GPI-anchored or transmembrane glycoproteins from the endoplasmic reticulum (ER) to the Golgi apparatus in CHO cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:FLT3-ITD+ MV4-11, Molm13; FLT3-WT HL-60, THP-1, OCI-AML3, Kasumi-1, KG-1α
-
Concentration:60-100 μM
-
Incubation Time:48 h
-
Result:Significantly inhibited the viability of FLT3ITD+ MV4-11 and Molm13 cells in a dose-dependent manner.
Had no obvious effect on FLT3WT AML cell lines at the same concentrations.
-
Cell Line:FLT3-ITD+ Molm13 AML cell line
-
Concentration:60-100 μM
-
Incubation Time:48 h
-
Result:Induced a dose-dependent decrease in cell proliferation.
Significantly reduced EdU-positive cell percentages at 100 μM compared to vehicle control.
-
Cell Line:FLT3-ITD+ Molm13 AML cell line
-
Concentration:60-100 μM
-
Incubation Time:48 h
-
Result:Promoted apoptosis.
Significantly increased the percentage of apoptotic cells at 100 μM compared to vehicle control.
In Vivo
[18F]HPA-12 (1.5 MBq; i.v.; single administration), a radiolabeled form of HPA-12, crosses the blood-brain barrier and accumulates in the brain of wild-type mice. Its uptake exhibits brain region dependence, with an average SUV of approximately 0.3 at 1 h post-injection[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B-NDG mice with Acute myeloid leukemia (AML) (6-8-week-old female; AML xenograft model via intravenous injection of 1×106 MV4-11-luc+ cells)[1]
-
Dosage:4 mg/kg (monotherapy);
4 mg/kg + 15 mg/kg Creno (combination therapy) -
Administration:s.c.; 5 days on, 2 days off; 2 cycles; i.p. (Creno, 5 days on, 2 days off; 2 cycles)
-
Result:Reduced spleen enlargement compared to untreated mice.
Lowered human CD33+/CD45+ cell burden in bone marrow compared to untreated mice.
Dramatically reduced bioluminescence signals on Day 27 when combined with Creno.
Prolonged survival compared to untreated, HPA-12 monotherapy, or Creno monotherapy groups when combined with Creno.
Achieved the greatest reduction in spleen weight when combined with Creno.
Resulted in the lowest human CD33+/CD45+ cell burden in bone marrow when combined with Creno.
Led to the lowest leukemia burden in bone marrow and spleen as measured by human CD45 IHC staining when combined with Creno.
Caused slight body weight loss in monotherapy group; showed no obvious body weight change in combination group.
-
Animal Model:C57Bl6/J mice (male, 2 months of age)[2]
-
Dosage:1.5 MBq
-
Administration:i.v.; single dose
-
Result:Reached a standard uptake value (SUV) of ~0.3 in brain one hour post-injection.
Showed highest regional SUV in the olfactory bulb, followed by cortex, hypothalamus, basal forebrain septum, and cerebellum.
Achieved brain uptake of 0.64%ID/g (hindbrain-midbrain), 0.70%ID/g (forebrain), and 0.89%ID/g (olfactory bulb) post-perfusion.
Revealed 12% of radioactivity as intact target reagent, 20% as free 18F, 1% as an unknown metabolite, and 67% bound to brain cells via HPLC analysis of brain tissue.
Chemical Information
-
CAS. Nr. 383418-30-2
-
Appearance Solid
-
Molecular Weight 363.53
-
Formel C22H37NO3
-
Color White to off-white
-
SMILES
CCCCCCCCCCCC(N[C@@H](CO)C[C@H](O)C1=CC=CC=C1)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 2 mg/mL (5.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Mitophagy Solutions
Mitophagy is the selective autophagic degradation of mitochondria and functions as a mitochondrial quality-control pathway that removes damaged, depolarized, excess, or developmentally programmed mitochondria. The pathway links mitochondrial damage recognition, autophagosome recruitment, lysosomal delivery, and mitochondrial turnover to phenotypes such as mitochondrial homeostasis, oxidative-stress control, metabolic remodeling, differentiation, and neurodegeneration-related mitochondrial fidelity. The best-characterized damage-induced pathway is the PINK1-Parkin axis. Parkin is recruited selectively to impaired mitochondria and promotes their autophagic elimination, while mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, recruits Parkin, and activates Parkin-dependent mitophagy. PINK1 also phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity, and PINK1-driven ubiquitin phosphorylation creates a feed-forward signal for recruiting autophagy machi
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Sun X, et al. Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axis. Nat Commun. 2025;16(1):1358. Published 2025 Feb 4. [Content Brief]
[2]. Crivelli SM, et al. Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications. J Alzheimers Dis. 2017;60(3):783-794. [Content Brief]
[3]. Yasuda S, et al. A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis. J Biol Chem. 2001;276(47):43994-44002. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7508 mL | 13.7540 mL | 27.5080 mL | 68.7701 mL |
| 5 mM | 0.5502 mL | 2.7508 mL | 5.5016 mL | 13.7540 mL |